Projects per year
Most patients present for catheter ablation of atrial fibrillation (CAAF) with residual or full effect of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). In daily practice, it has been observed that the activated clotting time (ACT) was actually poorly sensitive to the effect of DOACs and that patients on DOACs required more unfractionated heparin (UFH) to achieve the ACT target of 300 s during the procedure, leading some authors to worry about potential overdosing. Conversely, we hypothesize that these higher doses of UFH are necessary to achieve adequate hemostasis during CAAF regardless of the residual effect of DOACs. During CAAF, thrombosis is promoted mainly by the presence of thrombogenic sheaths and catheters in the bloodstream. Preclinical data suggest that only high doses of DOACs are able to mitigate catheter-induced thrombin generation, whereas low dose UFH already do so. In addition, the effect of UFH seems to be lower in patients on DOACs, compared to patients on VKAs, explaining part of the differences observed in heparin requirements. Clinical studies could not identify increased bleeding risk in patients on DOACs compared to those on VKAs despite similar efficacy during CAAF procedures. Moreover, targeting a lower ACT was associated with an increased periprocedural thrombotic risk for both DOAC and VKA patients. Therefore, the low sensitivity of the ACT to the residual effect of DOACs should not be a major concern in its use in the interventional cardiology laboratory.
|Journal||Frontiers in cardiovascular medicine|
|Publication status||Published - 29 Mar 2022|
- activated clotting time
- atrial fibrillation
- catheter ablation
- direct oral anticoagulant
- unfractionated heparin
FingerprintDive into the research topics of 'Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?'. Together they form a unique fingerprint.
- 2 Active
Clinical Pharmacology Research Group
Douxfils, J., Dogne, J., Musuamba Tshinanu, F., MASEREEL, B., Wieers, G., Haguet, H., RONVAUX, L., Donis, N., Morimont, L., Evrard, J., Siriez, R., Gillot, C., FAVRESSE, J., BOUVY, C., Djokoto, H., Didembourg, M., David, C., Melchionda, S., Maloteau, V., Boucher, A., Devel, P., Modaffari, E., Vandeputte, M., De Messemaeker, A., Decarpentrie, J., Vassart, J. & De Groote, A.
1/04/22 → …
Project: Research Axis
The BIOCOAG project : Biological assessment of the control of anticoagulation
Douxfils, J., MULLIER, F., Dogne, J., Siriez, R. & Evrard, J.
1/09/11 → …